Long-Term Impact of Neonatal Intake of Oleanolic Acid on the Expression of AMP-Activated Protein Kinase, Adiponectin and Inflammatory Cytokines in Rats Fed with a High Fructose Diet by Matumba, Mashudu Given et al.
nutrients
Article
Long-Term Impact of Neonatal Intake of Oleanolic
Acid on the Expression of AMP-Activated Protein
Kinase, Adiponectin and Inflammatory Cytokines
in Rats Fed with a High Fructose Diet
Mashudu Given Matumba 1, Ademola Olabode Ayeleso 2, Trevor Nyakudya 3 ,
Kennedy Erlwanger 4, Novel N. Chegou 5 and Emmanuel Mukwevho 1,*
1 Department of Biochemistry, Faculty of Natural and Agricultural Science, North West University,
Mafikeng Campus, Private Bag X2046, Mmabatho 2735, South Africa; mgmatumba@gmail.com
2 Department of Biochemistry, Faculty of Science, Adeleke University, P.M.B. 250, Ede, Osun State 232101,
Nigeria; ademola.ayeleso@adelekeuniversity.edu.ng
3 Department of Human Anatomy and Physiology, Faculty of Health Sciences, University of Johannesburg,
Doornfontein, Johannesburg 2028, South Africa; trevorn@uj.ac.za
4 School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Parktown,
Johannesburg 2193, South Africa; kennedy.erlwanger@wits.ac.za
5 DST-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research
Council Centre for Tuberculosis Research, Department of Biomedical Sciences, Division of Molecular
Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,
Tygerberg 7505, South Africa; novel@sun.ac.za
* Correspondence: emmanuel.mukwevho@nwu.ac.za; Tel.: +27-18-389-2854
Received: 23 October 2018; Accepted: 7 December 2018; Published: 22 January 2019


Abstract: AMP-activated protein kinase (AMPK) is known to regulate both glucose and lipid
metabolism, which play vital roles in the development of metabolic syndrome. One way of regulating
AMPK is through hormonal activation using adiponectin. Patients diagnosed with type-2 diabetes
(T2D) and obesity exhibit low adiponectin concentration levels in their blood. Moreover, studies
have also shown that inflammatory processes play a significant role in the etiology of these metabolic
diseases. In this study, the long-term effects of neonatal intake of oleanolic acid (OA) on the
AMPK gene, genes associated with glucose transport and lipid metabolism, adiponectin levels,
and inflammatory biomarkers in rats fed with a high fructose diet were investigated. Seven day old
pups were randomly divided into five groups and treated as follows; 0.5% dimethylsulphoxide v/v
in distilled water vehicle control (CON), oleanolic acid (OA, 60 mg/kg), high fructose diet (HF, 20%
w/v), high fructose diet combined with oleanolic acid (HF+OA), and high fructose diet combined
with metformin (HF+MET, 500 mg/kg). The treatments were administered once daily until day
14. The rats were then weaned at day 21 and fed standard rat chow and had ad libitum access to
plain drinking water until day 112. The quantitative polymerase chain reaction (qPCR) was used
to analyze the gene expressions of AMPK, Glut-4, Cpt-1, AdipoR1, AdipoR2, TNF-α, and IL-6 in the
skeletal muscles. Bio-Plex Pro magnetic bead-based assay was used to measure plasma levels of
inflammatory markers (TNF-α, IL-6, VEGF, and MCP-1) while ELISA kits were used to measure
adiponectin concentration in blood plasma. The results obtained in this study showed that neonatal
supplementation with OA significantly increased AMPK gene expression approximately ~4-fold in
OA fed rats compared to those that were fed with HF alone. In addition, glut-4 gene expression
was also significantly higher in the OA treatment group compared to all the other experimental
groups except the CON group whereas Cpt-1 gene was more expressed when OA was administered
alone. Together, these results indicated that OA can play a role in glucose and lipid metabolism gene
regulation. Furthermore, the results showed that the OA group had ~1.5-fold increase in adiponectin
concentration when comparedto the HF group. Moreover, HF increased levels of inflammatory
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cytokines, which was attenuated by neonatal administration of OA. Plasma concentration and gene
expression in the skeletal muscle for TNF-α and IL-6 were significantly increased in rats that were
treated with HF alone when compared to all the other groups. On the contrary, the high levels of
TNF-α and IL-6 were reduced when OA was administered. These findings suggest that intake of
oleanolic acid during the neonatal stage of development could be a potential strategic intervention
for the long-term prevention of metabolic diseases such as T2D and obesity.
Keywords: type-2 diabetes; obesity; oleanolic acid; metabolic syndrome; high fructose diet; AMPK;
adiponectin; inflammatory cytokines
1. Introduction
Type 2 diabetes (T2D) is an epidemic health challenge all over the world as a result of the high
prevalence of obesity [1]. It is important to note that obesity and T2D are causally linked through
their association with the development of skeletal muscle insulin resistance [2]. Insulin resistance is
described as a condition in which circulating insulin becomes non-functional at target tissues, namely
skeletal muscle, adipose tissue, and the liver [3]. T2D was initially thought to be a disease exclusive
to adults, however there is a rising incidence of T2D in adolescents in parallel with the increasing
prevalence of obesity amongst children [4]. Consequently, there is huge interest in studies within this
field to elucidate mechanisms of this epidemic [5].
AMP-activated protein kinase (AMPK) is a well-studied and described enzyme which serves
asthe master regulator of both lipid and glucose metabolic pathways. An extensive literaturesurvey
has shown that dysregulation of AMPK plays a critical role in the etiology of T2D and obesity [6].
Once AMPK is activated, it increases both fatty acid uptake and β-oxidation in the mitochondria
with a concomitant increase in glucose uptake through the translocation of glucose transporter 4
(GLUT-4). Glut-4 is the major glucose transporter protein found in the intercellular vesicles across
the plasma membrane in the skeletal muscles [7]. In T2D, translocation of Glut-4 is limited, resulting
in hyperglycaemia. Excess lipids also play a significant role in the development of T2D. Carnitine
palmitoyltransferase (CPT-1) is the gatekeeper for the entry of fatty acids into the mitochondria [8] for
oxidation. Both lipid oxidation and glucose uptake are impaired in T2D and obese persons, owing
to the fact that these two pathways are regulated together by AMPK. As such, this enzyme has
now become a vital target in the development of therapeutics much needed to ameliorate the health
outcomes associated with T2D and obesity [6].
The adipose tissue secretes various bioactive proteins and hormones into the circulation named
adipo-cytokines essential in T2D [9]. One such critical hormone secreted by the adipose tissue is
adiponectin. Adiponectin is a protein hormone that plays an important role in the modulation
of glucose and lipid metabolism in insulin-sensitive tissues in both humans and animals [9,10].
Furthermore, literature has reported that adiponectin is associated with obesity-related insulin
resistance and T2D [11]. It has been demonstrated that adiponectin’s mechanism of action is through
activation of AMPK, which then regulates both glucose and lipid metabolism [12]. Lastly, research
studies have also shown that patients suffering from T2D and obesity related to insulin resistance
are associated with decreased adiponectin concentrations in circulating blood [13]. The reason for
this is that obesity and T2D can result from adiponectin deficiency, thus making this hormone a good
target for possible therapeutic interventions, focusing on the possibility that adiponectin treatment
may improve T2D and obesity-related insulin resistance [11].
Inflammatory processes also play a significant role in the etiology of T2D and obesity [14].
Consequentially, T2D is associated with an increased circulating concentration of inflammatory
biomarkers [15]. For example, tumor necrosis factor-α (TNF-α) is an adipo-cytokine involved in
inflammation and is found to be increased in the metabolic syndrome, T2D and obesity, and therefore
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contributes to insulin resistance by interfering with insulin receptor signaling [16,17]. Furthermore,
it has also been shown that IL-6 is elevated in insulin resistant and obese individuals and as such,
its plasma levels correlate with the degree of insulin resistance [6]. In this present study, we also
analyzed the blood plasma concentration of monocyte chemoattractant protein-1 (MCP-1) and vascular
endothelial growth factor (VEGF). The monocyte chemoattractant protein-1 (MCP-1), which signals
to macrophages through the C-C chemokine receptor 2 (CCR2), is strongly correlated with T2D and
obesity [18]. Circulating MCP-1 has been found significantly increased in patients with T2D [19].
Similarly, another study showed that plasma VEGF concentration was high in diabetic patients
who were hospitalized because of poor glycaemic control compared to the concentration in healthy
subjects [20]. Vascular endothelial growth factor (VEGF) is one of the major growth factors that have
an adverse effect on ocular neovascular diseases such as diabetic retinopathy [21].
Current therapeutic approaches in the management of metabolic dysfunction involve the use of
conventional drugs. The use of these pharmaceutical drugs has been associated with the development
of undesirable adverse side-effects [22]. Moreover, their cost is beyond the reach of many, particularly
in resource-limited African rural and some urban areas. As such, most rural and urban based
people make use of plant based ethno-medicines for their primary health care. The efficacy of
ethno-medicines in the management of several metabolic disorders has been attributed to the presence
of bioactive phytochemicals [22]. One such phytochemical, that we selected for the current study,
is oleanolic acid (OA).
Oleanolic acid (OA) is a bioactive pentacyclin triperpenoid compound isolated from plants
belonging to the family Oleaceae. OA is known to exert anti-diabetic effects among other health
promoting characteristics, with no adverse effects [23,24]. Oleanolic acid has also been shown to
significantly lower blood glucose and weight loss in diabetic rats [25]. However, its actual mechanism
of action in conferring the anti-diabetic effects is not well defined. Most studies that investigated the
therapeutic efficacy of OA made use of adult animal experimental models. Until recently in studies by
references [26,27], no studies had been conducted targeting the neonatal period, a critical window of
developmental plasticity. Therefore, the aim of this present study was to investigate the long-term
impact of neonatal intake of OA on the development of metabolic diseases such as T2D and obesity in
rats that were fed a high fructose diet.
2. Materials and Methods
2.1. Animals
This study was conducted using forty male Sprague Dawley rat pups obtained from the Central
Animal Services of the University of the Witwatersrand, South Africa. Seven day old pups were
randomly divided into the five groups namely the 0.5% v/v dimethylsulphoxide in distilled water
vehicle control (CON), Oleanolic acid (OA, 60 mg/kg), High fructose diet (HF, 20% w/v), High
fructose diet combined with oleanolic acid (HF+OA), and High fructose diet combined with metformin
(HF+MET, 500 mg/kg). The doses of oleanolic acid and metformin used werepreviouslyused in other
metabolic studies in rats [28,29]. The treatments were administered by orogastric gavage (10 mL/kg)
once dailyuntil day 14. This initial treatment targeted one of the windows of developmental plasticity
during which interventions can induce epigenetic changes that have long lasting outcomes on the
disease state or health of the individual [30]. The rats were then weaned on day 21 and fed with
standard rat chow and had ad libitum access to plain drinking water until day 111 to investigate
whether the neonatal interventions could have an impact on health outcomes later in life. At the
end of the experiment on day 112, the rats were euthanized with sodium pentobarbital (200 mg/kg
body weight; Euthanaze®, Centaur Laboratories, Johannesburg, South Africa). Blood was collected
by cardiac puncture and samples were dispensed into plain and heparin coated tubes. The blood
samples were centrifuged and the plasma and serum then collected. Skeletal muscle samples were
dissected out, snap frozen in liquid nitrogen, and stored at−80 ◦C until further assays were performed.
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All animal experiments were conducted in accordance with protocols approved by theAnimal Ethics
Screening Committee (AESC) of the University of Witwatersrand, Johannesburg, South Africa (AESC
approval number 2014/47/D).
2.2. Measurement of Adiponectin Concentration Using ELISA
A rat adiponectin ELISA kit (Sigma-Aldrich, St. Louis, MO, USA) was used to measure
adiponectin concentration in blood plasma according to the manufacturer’s protocol. Briefly, 1×
wash buffer was prepared by diluting the 20× wash buffer with deionized water and the 1× ELISA
buffer was also prepared by diluting the 5× ELISA buffer with deionized water. The rat adiponectin
protein standard was reconstituted with 1 mL of deionized water and serial dilutions of the standard
were prepared. Then 1× biotinylated rat adiponectin detection antibody solution was prepared by
diluting the detection antibody 1:1000 in 1× ELISA buffer and 1× HRP-Streptavidin solution was
prepared by diluting HRP solution 1:100 in 1× ELISA buffer.
The protein standard and samples were added into appropriate wells (100 µL to each well) and
the plate was incubated at room temperature for 2.5 h with gentle shaking. The solution was discarded
and the wells were washed 4 times with 300 µL 1× wash solution. Then 100 µL of 1× prepared
biotinylated detection antibody was added to each well and the plate was incubated for 1 h at room
temperature with gentle shaking. The solution was discarded and the wells were washed 4 times
with 300 µL 1× wash solution again. Then 100 µL of the prepared HRP-Streptavidin solution was
added to each well and the plate was incubated for 45 min at room temperature with gentle shaking.
The solution was discarded and the wells were washed 4 times with 300 µL 1× wash solution for
the last time. Then 100 µL of ELISA colorimetric TMB reagent was added to each well and the plate
was incubated for 30 min at room temperature in a dark room with gentle shaking. Lastly, 50 µL of
stop solution was added to each well and absorbance was measured at 450 nm immediately with a
spectrophotometer. The protein standard curve was generated and the unknown concentration of the
samples was determined.
2.3. Measurement of Gene Expression Using qPCR Analysis
2.3.1. RNA Extraction
Total RNA was isolated using Trizol (Life Technologies, Carlsbad, CA, USA). The frozen skeletal
muscle tissue was crushed in liquid nitrogen using a pestle and mortar and, 1 mL of trizol was
added to 200 mg of tissue sample. The mixture was homogenized for 3 min while working on ice.
The homogenate was then vortexed vigorously after addition of 200 µL of chloroform and then
incubated on ice for 15 min. The homogenate was then centrifuged at 12,000× g for 15 min at 4 ◦C to
get the phase spectrum. The aqueous phase was then transferred to a new fresh tube. The total RNA
was precipitated by incubating the solution for 10 min in ice after addition of 0.5 mLof isopropanol.
After incubation, the solution was centrifuged for 10 min at 12,000× g at 4 ◦C and the supernatant was
removed. The pellet was washed with 70% ethanol and then centrifuged for 10 min at 7500× g at 4 ◦C.
The supernatant was removed and the total RNA pellet was dissolved in 50 µL of RNase free water.
Total RNA concentration and quality was measured using the NanoDrop Lite Spectrophotometer
(Thermo Scientific, Johannesburg, South Africa). The integrity of the total RNA was analyzed using 1%
agarose gel electrophoresis; briefly 1 g of agarose was dissolved in 100 mLof TAE buffer by heating the
mixture with a microwave for 60 s. The mixture was allowed to cool down to at least 50 ◦C, and then
1.5 µL of ethidium bromide was added. The solution was poured in the gel tray, the comb was inserted,
and the gel was allowed to solidify. The samples were loaded in the wells after being mixed with the
loading dye. The electrophoresis was run for 45 min at 100 volts and TAE buffer was also used as a
tank buffer. The gel was viewed under the doc machine (Bio-Rad Laboratories, Hercules, CA, USA).
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2.3.2. cDNA Synthesis
The cDNA was synthesized using the SuperScript VILO cDNA Synthesis kit (Thermofisher
Scientific, Johannesburg, South Africa) according to the manufacturer’s protocol. Briefly, master mix
was prepared by mixing together the 5× VILO Reaction mix and the 10× SuperScript enzyme mix
while working on ice. The volume of RNA required to make a concentration of 2.5 µg was calculated
and DEPC-treated water was used to compensate the volume to a final of 20µL in all reaction tubes.
The tube contents were gently mixed and then incubated for 10 min at 25 ◦C, then followed by 42 ◦C
incubation for 60 min. The reaction was terminated by incubation at 85 ◦C for 5 min. All incubations
were done in the T100 Thermal Cycler (Bio-Rad, Singapore). The cDNA was stored at −20 ◦C until use.
2.3.3. Real-Time PCR
Real-Time PCR was performed using the PowerUp SYBR Green master mix (Applied Biosystems,
Life Technologies, USA) according to the manufacturer’s protocol. The primers (Table 1) and the
PowerUp SYBR Green master mix were mixed together appropriately according to the volumes given
by the manufacturer. The cDNA template was mixed with RNase-free water. Solutions were then
transferred to appropriate wells in the 96 well plate and the template was added lastly. The plate was
then sealed with an optical adhesive cover. The step One plus Real-Time PCR system thermal cycling
block instrument (Applied Biosystems, Life Technologies, USA) was used. The reaction plate was
placed in the instrument and the thermal cycling conditions were set then the run was started.
Table 1. List of primers used in the study.
Genes Forward Primer (F) and Reverse Prime (R)
AdipoR1 F: 3
′-AAGCACCGGCAGACAAGAGC-5′
R: 3′-AGGAAGAACCAGCCCATCTG-5′
AdipoR2 F: 3
′-CTGTGTGCTGGGCATTGCAG-5′
R: 3′-AGCCTATCTGCCCTATGGTG-5′
AMPK-α F: 5
′-GGCAAAGTGAAGATTGGAGAACA-3′
R: 5′-AACTGCCACTTTATGGCCTGT C-3′
Glut-4 F: 5
′-GCAGCGAGTGACTGGACCA-3′
R: 5′-CCAGCCACGTTGCATTGTAG-3′
CPT-1 F: 5
′-CGGTTCAAGAATGGCATCATC-3′
R: 5′-TCACACCCACCACCACGAT-3′
TNF-α F: 5
′-CATCTTCTCAAAATTCGAGTGACAA-3′
R: 5′-TGGGAGTAGACAAGGTACAACCC-3′
IL-6 F: 5
′-GCCACTGCCTTCCCTACTTCA-3′
R: 5′-GACAGTGCATCATCGCTGTTCA-3′
Actin F: 5
′-GACGAGGCCCAGAGCAAGAGA-3′
R: 5′-GGGTGTTGAAGGTCTCAAACA-3′
2.4. Measurements of Inflammatory Markers Concentration in Blood Plasma
Bio-Plex Pro magnetic bead-based assays (Bio-Rad Laboratories, Hercules, CA, USA) were used to
measure plasma levels of inflammatory markers (TNF-α, IL-6, VEGF, and MCP-1) using the Luminex
technology. Samples were evaluated undiluted. Briefly, samples were added to a mixture of fluorescent
magnetic beads bound with specific anticytokine primary antibodies, resulting in binding of the
cytokines to the bead with the corresponding antibody. The biotinylated anticytokine secondary
antibodies were then added and allowed to bind to the cytokine-bead complex. After washing,
followed by the addition of fluorescent phycoerythrin-conjugated streptavidin, assays were read on
the Bio Plex 200 platform (Bio Rad Laboratories, Hercules, CA, USA). The standard curve for all the
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analytes ranged from 3 to 12,000 pg/mL. Bio-Plex manager software version 6.1 (Bio Rad Laboratories,
USA) was used for bead acquisition and analysis.
2.5. Statistics
Data were expressed as mean ± SD. Analysis of statistical significance of differences in
measurements between samples was done by one-way ANOVA (GraphPad Prism version 6). p<0.05
was considered statistically significant.
3. Results
3.1. Gene Expression of AMPK
Figure 1 shows the influence of OA on AMPK gene expression in HF-induced rats. The results
in Figure 1 show the gene expression of AMPK in the skeletal muscles. Neonatal administration of
fructose (HF) significantly decreased AMPK gene expression when compared to the control group.
However, neonatal supplementation with oleanolic acid (HF+OA) resulted in ~4-fold increase of
AMPK gene expression when compared to the HF group. Furthermore, rats given metformin and the
high fructose diet (HF+MET) showed ~1.6-fold increase of AMPK gene expression when compared to
the HF group.
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Figure 1. Gene expression of AMPK gene in the skeletal muscles of rats. The expression ratio of the
gene is presented in relative units. Data is presented as mean± SD. The p value representing the degree
of significance difference amongst the groups is indicated as ** p < 0.01; *** p < 0.001; **** p < 0.0001.
CON (Control), OA (Oleanolic acid), HF (High fructose diet), MET (Metformin).
3.2. Gene Expression of Glut-4 and Cpt-1
Figure 2a shows the Glut-4 gene expression while Figure 2b shows the Cpt-1 gene expression
in the skeletal muscles. Glut-4 gene expression was significantly higher in the OA treatment group
compared to ll the other experime tal group , except for the CON group. The HF+OA group howed
~1.5-fold G ut-4 gene expression when compared to the HF group whereas there was no significant
difference in the Glut-4 gene expression between th HF and HF+MET group (Figur 2a).
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Figure 2. Gene expression of Glut-4 (a) and Cpt-1 in the skeletal muscles (b). The expression ratio
of the gene is presented in relative units. Data is presented as mean ± SD. The p value representing
the degree of significance difference amongst the groups is indicated as * p < 0.1; *** p < 0.001;
**** p < 0.0001; ns = no significant difference. CON (Control), OA (Oleanolic acid), HF (High fructose
diet), MET (Metformin).
The rats that were treated with OA neonatally showed a markedly significant ~18.8-fold increase
in Cpt-1 gene expression when compared to the CON group whereas the HF+MET group had
~18.5-fold increase in Cpt-1gene expression when compared to the CON group. The HF group had
the lowest Cpt-1gene expression when compared to all the other groups except with the CON group.
Both oleanolic acid and metformin were able to enhance the Cpt-1gene expression (Figure 2b).
3.3. Adiponectin Concentration
Figure 3 shows the concentration of adiponectin in blood plasma in response to various treatments.
In this study, neonatal treatment with HF significantly decreased the concentration of plasma
adiponectin compared to all the other groups (p < 0.05). The OA group had ~1.5-fold increase
in adiponectin concentration when compared to the HF group. Neonatal treatment with oleanolic acid
(HF+OA) and metformin (HF+MET) prevented the fructose-induced decrease in adiponectin levels
and caused ~1.5-fold and ~1-fold increase respectively, in adiponectin concentration.
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Figure 3. Concentration of adiponectin in the blood plasma. Concentration is presented in ng/Ml and
data is presented as mean ± SD. The p value representing the degree of significance difference amongst
the groups is indicated as ** p < 0.01; *** p < 0.001; **** p < 0.0001. CON (Control), OA (Oleanolic acid),
HF (High fructose diet), MET (Metformin).
3.4. Gene Expression of Adiponectin Receptors
Figure 4a shows the AdipoR1 gene expression while Figure 4b shows the AdipoR2 gene expression
in the skeletal muscles. High fructose diet significantly decreased the AdipoR1 gene expression when
compared to all the other treatment groups except for the CON group. The OA group showed ~2-fold
increase in AdipoR1 gene expression when compared to the CON group. In addition, the HF+OA and
HF+MET groups showed ~1.4 and ~1.6-fold increases respectively in AdipoR1 gene expression when
compared to the HF group (p < 0.05). These results indicate that AdipoR1 gene was more expressed
following neonatal treatments with OA and MET, whereas HF negatively decreased its expression
as shown in Figure 4a. However, AdipoR2 was not well expressed in all the groups compared to the
CON group. Furthermore, there was no significance difference in AdipoR2 gene expression on rats fed
with high fructose diet (HF) when compared to rats in groups that received treatment (HF+OA and
HF+MET) (Figure 4b).
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3.5. Inflammatory Biomarkers Concentration and Gene Expression
Figure 5a shows the skeletal muscle TNF-α gene expression and Figure 5b shows the concentration
of TNF-α in the blood plasma. TNF-α gene expression was significantly increased in rats that were
treated with HF alone when compared to all other groups. Neonatal treatment with OA and MET
prevented the fructose-induced increase in the expression of TNF-α. The HF group had ~7.8-fold
increase in TNF-α concentration when compared to the CON group. On the other hand, rats treated
with OA only had the lowest TNF-α concentration when compared to other treatment groups.
Furthermore, HF+MET and HF+OA group had lower TNF-α concentration when compared to the
HF group.Nutrients 2018, 10, x FOR PEER REVIEW  10 of 15 
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In Figure 6a, there was ~24-fold increase of IL-6 gene expression in the skeletal muscles of
fructose-f d rats when compared to all other groups. Neonatal treatment with oleanolic acid (HF+OA)
and metformin (HF+MET) reversed the high expression of IL-6 expression induced by high fructose
diet (HF). Figure 6b shows that the HF treated rats had ~3.7-fold IL-6 concentration increase when
compared to the CON group. Both HF+OA and HF+MET groups had low IL-6 concentrations when
compared to the HF group.
Figure 7a shows the concentration of IL-6 while Figure 7b shows the concentration of MCP-1 in the
blood plasma. The results showed that neonatal fructose (HF) treatment caused a significant increase
(~6.4-fold) in the concentration of MCP-1 when compared to the CON group (p < 0.05). The neonatal
treatment with OA alone and a combination of high fructose diet with either oleanolic acid (HF+OA)
or metformin (HF+MET) lowered MCP-1 concentration when compared to the CON and HF group.
Figure 7b shows that fructose treatment (HF) caused a ~4.3-fold increase in the concentration of VEGF
when compared to the control. Neonatal treatment with oleanolic acid alone (OA) and a combination
of fructose with oleanolic acid (HF+OA) and metformin (HF+MET) lowered the VEGF concentration
when compared to the HF.
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4. Discussion
This study investigated the long-term impact of neonatal intake of oleanolic acid and fructose on
the gene expression of AMPK and other genes that play a key role in glucose and lipid metabolism.
Our findings show that oleanolic acid significantly increased AMPK gene expression with ~4-fold in
high fructose-fed rats that were treated with oleanolic acid when compared to those that were fed with
high fructose diet alone. The result reveals that oleanolic acid regulates AMPK and could be a potential
therapeutic agent in the management of T2D and obesity. AMPK is a fuel sensor for glucose and
lipid metabolism [31]. Activated AMPK in skeletal muscles stimulates glucose uptake by increasing
GLUT-4 translocation and fatty acid oxidation in lipid metabolism [6]. In this study, oleanolic acid
significantly increased Glut-4 gene expression with ~1.5-fold in concomitantly high fructose-fed rats
when compared to the rats that wer fed with high fructose diet alone. Since GLUT-4 is s en as one
of the targets for ther peutic mod lities and was significantly increased by OA, these findings are a
signifi ant step towards the better management and treatment of T2D and obesity [32].
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CPT-1 plays a crucial role in fatty acid β-oxidation as a gatekeeper for entry of fatty acids into the
mitochondria [7]. This study showed no significant difference in Cpt-1 gene expression between high
fructose-fed rats that were treated with oleanolic acid and those that were fed with a high fructose
diet alone. However, oleanolic acid administered alone was able to up-regulate Cpt-1 gene expression,
which promotes fatty acid uptake in the mitochondria for β-oxidation.
Findings from this study showed thatfructose reduced the concentration of adiponectin in plasma
and downregulated the gene expression of its receptors (AdipoR1 and AdipoR2) in skeletal muscles.
Previous studies have shown that the concentration of adiponectin and its receptors are down-regulated
in T2D and obesity-related insulin resistance [12,33]. Adiponectin has also been reported to improve
insulin sensitivity and reduce the risk of developing T2D [34]. The present study showed that
OA up-regulated adiponectin concentration by ~1-fold in rats that were fed a high fructose diet.
Furthermore, for adiponectin to elicit its effects, it has to bind first to its receptors (AdipoR1 and
AdipoR2). It was observed in this study that oleanolic acid significantly increased AdipoR1 gene
expression by ~1.4 fold in rats that were treated with oleanolic acid when compared to the rats
that were given the high fructose diet alone. The improvement of AdipoR1 gene expression in the
skeletal muscle is a positive effect since adiponectin exerts its response through binding to AdipoR1.
Therefore, the results shown in Figure 4a indicated that OA influenced the expression of AdipoR1
gene expression in a positive manner. On the other hand, AdipoR2 was poorly expressed in all the
groups compared to the control. These findings confirm previous reports that showed that AdipoR1
dominates in skeletal muscle whilst AdipoR2 predominates in the liver tissue [17,35], thus the low
expression of AdipoR2 in skeletal muscle was not unexpected. Systemic inflammatory markers are
risk factors for the development of T2D and metabolic dysfunction [36]. In this study, inflammatory
cytokines were increased in rats that were fed with a high fructose diet. These results are consistent
with other previous studies showing that inflammatory cytokine markers are elevated in insulin
resistance and obese individuals [6,15,16,19,37]. High fructose diet induced elevation in cytokine levels
and was attenuated when these rats were treated with oleanolic acid, indicating the potential of OA
in ameliorating symptoms of T2D and obesity. High fructose effects are consistent with the notion
that diet and in particular high carbohydrate levels, have deleterious effects on normal functioning
of metabolic processes of the cell and are a major contributor to health problems such as T2D and
obesity [38–46].
5. Conclusions
This study has shown that neonatal treatment with OA prevented the fructose-induced down
regulation of AMPK expression in skeletal muscles and decreased plasma level of adiponectin in
Sprague Dawley rats. Neonatal OA oral administration also prevented the fructose-induced increase
in the level of inflammatory cytokines, and increased the expression glucose transporter 4 gene (Glut-4)
that is responsible for glucose uptake and prevention of hyperglycaemia. These findings seem to
suggest that oleanolic acid could be used as an alternative prophylactic therapeutic agent against the
development of metabolic diseases such as T2D and obesity.
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